US20050113377A1 - 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors - Google Patents

2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors Download PDF

Info

Publication number
US20050113377A1
US20050113377A1 US10/974,893 US97489304A US2005113377A1 US 20050113377 A1 US20050113377 A1 US 20050113377A1 US 97489304 A US97489304 A US 97489304A US 2005113377 A1 US2005113377 A1 US 2005113377A1
Authority
US
United States
Prior art keywords
phenyl
alkyl
inflammation
cox
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/974,893
Inventor
Paul Beswick
Charanjit Bountra
Ian Campbell
Neil Mathews
Alan Naylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9718792.6A external-priority patent/GB9718792D0/en
Priority claimed from GBGB9727116.7A external-priority patent/GB9727116D0/en
Application filed by Individual filed Critical Individual
Priority to US10/974,893 priority Critical patent/US20050113377A1/en
Publication of US20050113377A1 publication Critical patent/US20050113377A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention relates to pyrazolo[1,5-b]pyridazine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.
  • COX-1 The enzyme cyclooxygenase (COX) has recently been discovered to exist in two isoforms, COX-1 and COX-2.
  • COX-1 corresponds to the originally identified constitutive enzyme while COX-2 is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors.
  • Prostaglandins generated by the action of COX have both physiological and pathological roles. It is generally believed that COX-1 is responsible for the important physiological functions such as maintenance of gastrointestinal integrity and renal blood flow.
  • the inducible form, COX-2 is believed to be responsible for the pathological effects of prostaglandins where rapid induction of the enzyme occurs in response to such agents as inflammatory agents, hormones, growth factors and cytokines.
  • a selective inhibitor of COX-2 would therefore have anti-inflammatory, anti-pyretic and analgesic properties, without the potential side effects associated with inhibition of COX-1.
  • pharmaceutically acceptable derivative is meant any pharmaceutically acceptable salt, solvate or ester, or salt or solvate of such ester, of the compounds of formula (I), or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.
  • salts referred to above will be the physiologically acceptable salts, but other salts may find use, for example in the preparation of compounds of formula (I) and the physiologically acceptable salts thereof.
  • Suitable pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts formed with inorganic or organic acids, preferably inorganic acids, e.g. hydrochlorides, hydrobromides and sulphates.
  • halogen is used to represent fluorine, chlorine, bromine or iodine.
  • alkyl as a group or part of a group means a straight or branched chain alkyl group, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl or t-butyl group.
  • R 0 is at the 3- or 4-position of the phenyl ring, as defined in formula (I).
  • R 0 is at the 6-position of the pyridazine ring, as defined in formula (I).
  • R 0 is F, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkoxy substituted by one or more fluorine atoms, or O(CH 2 ) 1-3 NR 4 R 5 . More preferably R 0 is F, C 1-3 alkoxy or C 1-3 alkoxy substituted by one or more fluorine atoms.
  • R 1 is C 1-4 alkylsulphonyl, C 1-4 alkoxy substituted by one or more fluorine atoms, O(CH 2 ) 1-3 CO 2 C 1-4 alkyl, O(CH 2 ) 1-3 SC 1-4 alkyl, (CH 2 ) 1 NR 4 R 5 , (CH 2 ) 1-3 SC 1-4 alkyl or C(O)NR 4 R 5 or, when R 0 is C 1-6 alkyl, C 1-4 alkoxy, O(CH 2 ) n NR 4 R 5 , may also be H.
  • R 1 is C 1-4 alkylsulphonyl, C 1-4 alkoxy substituted by one or more fluorine atoms or, when R 0 is C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxy substituted by one or more fluorine atoms, or O(CH 2 ) n NR 4 R 5 , may also be H.
  • R 2 is H.
  • R 3 is methyl or NH 2 .
  • R 4 and R 5 are independently C 1-3 alkyl or, together with the nitrogen atom to which they are attached, form a 5-6 membered saturated ring.
  • n is 1-3, more preferably 1 or 2.
  • R 0 is F, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkoxy substituted by one or more fluorine atoms, or O(CH 2 ) n NR 4 R 5 ;
  • R 1 is C 1-4 alkylsulphonyl, C 1-4 alkoxy substituted by one or more fluorine atoms, O(CH 2 ) n CO 2 C 1-4 alkyl, O(CH 2 ) n SC 1-4 alkyl, (CH 2 ) n SC 1-4 alkyl, (CH 2 ) n SC 1-4 alkyl or C(O)NR 4 R 5 or, when R 0 is C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkoxy substituted by one or more fluorine atoms, or O(CH 2 ) n NR 4 R 5 , may also be H;
  • R 2 is H;
  • R 3 is methyl or NH 2
  • R 0 is F, methyl, C 1-2 alkoxy, OCHF 2 , or O(CH 2 ) n NR 4 R 5 ;
  • R 1 is methylsulphonyl, OCHF 2 , O(CH 2 ) n CO 2 C 1-4 alkyl, O(CH 2 ) n SCH 3 , (CH 2 ) n NR 4 R 5 , (CH 2 ) n SCH 3 or C(O)NR 4 R 5 or, when R 0 is methyl, C 1-2 alkoxy, OCHF 2 , or O(CH 2 ) n N(CH 3 ) 2 , may also be H;
  • R 2 is H;
  • R 3 is methyl or NH 2 ;
  • R 4 and R 5 are both methyl or, together with the nitrogen atom to which they are attached, form a 5-6 membered saturated ring; and
  • n is 1-2.
  • group A2 there is provided a further group of compounds (group A2) wherein R 0 is F, C 1-3 alkoxy or C 1-3 alkoxy substituted by one or more fluorine atoms; R 1 is C 1-4 alkylsulphonyl, C 1-4 alkoxy substituted by one or more fluorine atoms or, when R 0 C 1-3 alkoxy or C 1-3 alkoxy substituted by one or more fluorine atoms, may also be H; R 2 is H; and R 3 is methyl or NH 2 .
  • R 0 is preferably at the 3- or 4-position of the phenyl ring and R 2 is preferably at the 6-position of the pyridazine ring.
  • the present invention encompasses all isomers of the compounds of formula (I) and their pharmaceutically acceptable derivatives, including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures).
  • Particularly preferred compounds of the invention are:
  • Compounds of the invention are potent and selective inhibitors of COX-2. This activity is illustrated by their ability to selectively inhibit COX-2 over COX-1.
  • the compounds of the present invention are of interest for use in human and veterinary medicine, particularly in the treatment of the pain (both chronic and acute), fever and inflammation of a variety of conditions and diseases.
  • conditions and diseases are well known in the art and include rheumatic fever; symptoms associated with influenza or other viral infections, such as the common cold; lower back and neck pain; headache; toothache; sprains and strains; myositis; neuralgia; synovitis; arthritis, including rheumatoid arthritis; degenerative joint diseases, including osteoarthritis; gout and ankylosing spondylitis; tendinitis; bursitis; skin related conditions, such as psoriasis, eczema, burns and dermatitis; injuries, such as sports injuries and those arising from surgical and dental procedures.
  • the compounds of the invention may also be useful for the treatment of other conditions mediated by selective inhibition of COX-2.
  • the compounds of the invention may inhibit cellular and neoplastic transformation and metastatic tumour growth and hence be useful in the treatment of certain cancerous diseases, such as colonic cancer.
  • Compounds of the invention may also prevent neuronal injury by inhibiting the generation of neuronal free radicals (and hence oxidative stress) and therefore may be of use in the treatment of stroke; epilepsy; and epileptic seizures (including grand mal, petit mal, myoclonic epilepsy and partial seizures).
  • Compounds of the invention also inhibit prostanoid-induced smooth muscle contraction and hence may be of use in the treatment of dysmenorrhoea and premature labour.
  • Compounds of the invention inhibit inflammatory processes and therefore may be of use in the treatment of asthma, allergic rhinitis and respiratory distress syndrome; gastrointestinal conditions such as inflammatory bowel disease, Chron's disease, gastritis, irritable bowel syndrome and ulcerative colitis; and the inflammation in such diseases as vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, type I diabetes, myasthenia gravis, multiple sclerosis, sorcoidosis, nephrotic syndrome, Bechet's syndrome, polymyositis, gingivitis, conjunctivitis and myocardial ischemia.
  • vascular disease migraine, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, type I diabetes, myasthenia gravis, multiple sclerosis, sorcoidosis, nephro
  • Compounds of the invention may also be useful in the treatment of ophthalmic diseases such as retinitis, retinopathies, uveitis and of acute injury to the eye tissue.
  • ophthalmic diseases such as retinitis, retinopathies, uveitis and of acute injury to the eye tissue.
  • Compounds of the invention may also be useful for the treatment of cognitive disorders such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntington's chorea, Parkinson's disease and Creutzfeldt-Jakob disease), and vascular dementia (including multi-infarct dementia), as well as dementia associated with intracranial space occupying lesions, trauma, infections and related conditions (including HIV infection), metabolism, toxins, anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment.
  • dementia particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntington's chorea, Parkinson's disease and Creutzfeldt-Jakob disease), and vascular dementia (including multi-infarct dementia), as well as dementia associated with intracranial space occupying lesions, trauma, infections and related conditions (including HIV infection), metabolism, toxins, anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age
  • a method of treating a human or animal subject suffering from a condition which is mediated by selective inhibition of COX-2 comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative.
  • a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a therapeutic agent for the treatment of a condition which is mediated by selective inhibition of COX-2, such as an inflammatory disorder.
  • a method of treating a human or animal subject suffering from an inflammatory disorder comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • Suitable agents for adjunctive therapy include pain relievers such as a glycine antagonist, a sodium channel inhibitor (e.g. lamotrigine), a substance P antagonist (e.g. an NK 1 antagonist), acetaminophen or phenacetin; a matrix metalloproteinase inhibitor; a nitric oxide synthase (NOS) inhibitor (e.g. an iNOS or an nNOS inhibitor); an inhibitor of the release, or action, of tumour necrosis factor ⁇ ; an antibody therapy (e.g.
  • a stimulant including caffeine; an H 2 -antagonist, such as ranitidine; a proton pump inhibitor, such as omeprazole; an antacid, such as aluminium or magnesium hydroxide; an antiflatulent, such as simethicone; a decongestant, such as phenylephrine, phenylpropanolamine, pseudoephedrine, oxymetazoline, epinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antitussive, such as codeine, hydrocodone, carmiphen, carbetapentane, or dextramethorphan; a diuretic; or a sedating or non-sedating antihistamine.
  • a stimulant including caffeine
  • an H 2 -antagonist such as ranitidine
  • a proton pump inhibitor such as omeprazole
  • an antacid such as aluminium
  • compositions comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof adapted for use in human or veterinary medicine.
  • Such compositions may conveniently be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or excipients.
  • the compounds of formula (I) and their pharmaceutically acceptable derivatives may be formulated for administration in any suitable manner. They may, for example, be formulated for topical administration or administration by inhalation or, more preferably, for oral, transdermal or parenteral administration.
  • the pharmaceutical composition may be in a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable derivatives.
  • the pharmaceutical composition may take the form of, for example, tablets (including sub-lingual tablets), capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.
  • the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.
  • the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravascularly or subcutaneously).
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • formulatory agents such as suspending, stabilising and/or dispersing agents.
  • For administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably with an added preservative.
  • the active ingredient may be in powder form for reconstitution with a suitable vehicle.
  • the compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compounds of the invention may also be used in combination with other therapeutic agents.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent.
  • compositions comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention.
  • the individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
  • a proposed daily dosage of a compound of formula (I) for the treatment of man is 0.01 mg/kg to 500 mg/kg, such as 0.05 mg/kg to 100 mg/kg, e.g. 0.1 mg/kg to 50 mg/kg, which may be conveniently administered in 1 to 4 doses.
  • the precise dose employed will depend on the age and condition of the patient and on the route of administration. Thus, for example, a daily dose of 0.25 mg/kg to 10 mg/kg may be suitable for systemic administration.
  • R 0 to R 5 and n are as defined in formula (I) above unless otherwise stated;
  • Hal is a halogen, such as Br or I;
  • X ⁇ is a counterion, such as I ⁇ ; and
  • alkyl is as previously defined.
  • compounds of formula (I) may be prepared by reacting a compound of formula (II) or a protected derivative thereof with a boronic acid of formula (III) or a suitable derivative thereof in the presence of a suitable transition metal catalyst.
  • Suitable derivatives of formula (III) include boronic acid esters, such as those described in R. Miyaura et al, J. Org. Chem., 1995, 60, 7508-7510.
  • the reaction is carried out in a solvent, such as an ether (e.g. 1,2 dimethoxyethane); in the presence of a base, such as an inorganic base (e.g. sodium carbonate); and employing a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0).
  • compounds of formula (I) wherein R 3 is C 1-6 alkyl may be prepared by oxidising a compound of formula (IV) or a protected derivative thereof under conventional conditions.
  • the oxidation is effected using a monopersulfate compound, such as potassium peroxymonosulfate (known as OxoneTM) and the reaction is carried out in a solvent, such as an aqueous alcohol, (e.g. aqueous methanol), and at between ⁇ 78° C. and ambient temperature.
  • a monopersulfate compound such as potassium peroxymonosulfate (known as OxoneTM)
  • a solvent such as an aqueous alcohol, (e.g. aqueous methanol), and at between ⁇ 78° C. and ambient temperature.
  • compounds of formula (I) wherein R 1 is C 1-6 alkylsulphonyl may be prepared by oxidising a compound of formula (V) or a protected derivative thereof under conventional conditions. Conveniently the oxidation is effected in the manner described just above for process (B).
  • compounds of formula (I) wherein R 1 is C 1-6 alkoxy substituted by one or more fluorine atoms may be prepared by reacting an alcohol of formula (VI) or a protected derivative thereof with a halofluoroalkane under conventional conditions.
  • a solvent such as a polar solvent (e.g. N,N-dimethylformamide)
  • a strong base such as an inorganic hydride (e.g. sodium hydride)
  • an inorganic hydride e.g. sodium hydride
  • compounds of formula (I) may be prepared by interconversion, utilising other compounds of formula (I) as precursors.
  • the following procedures are illustrative of suitable interconversions.
  • R 1 or R 2 represent C 1-4 alkyl substituted by one or more fluorine atoms
  • R 1 or R 2 represents C 1-4 alkyl substituted by one or more fluorine atoms
  • a suitable source of fluorine include, for example, diethylaminosulphur trifluoride.
  • the reaction is effected in the presence of a solvent, such as a halogenated hydrocarbon (e.g. dichloromethane), and at reduced temperature, such as ⁇ 78° C.
  • a solvent such as a halogenated hydrocarbon (e.g. dichloromethane)
  • Compounds of formula (I) wherein R 1 or R 2 represent C 1-6 hydroxyalkyl, and wherein the hydroxy group is attached to the carbon linked to the pyridazine ring, may be prepared by reduction of the compound of formula (I) wherein R 1 or R 2 represent the corresponding aldehyde or ketone.
  • Suitable reducing agents include hydride reducing agents, such as diisobutylaluminium hydride.
  • the reduction is effected in the presence of a solvent, such as a halogenated hydrocarbon (e.g. dichloromethane), and at reduced temperature, such as ⁇ 78° C.
  • a solvent such as a halogenated hydrocarbon (e.g. dichloromethane)
  • reduced temperature such as ⁇ 78° C.
  • Another process (F) for preparing compounds of formula (I) thus comprises deprotecting protected derivatives of compounds of formula (I).
  • the protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See, for example, those described in ‘Protective Groups in Organic Synthesis’ by Theodora W. Greene and Peter G. M. Wuts, second edition, (John Wiley and Sons, 1991), which also describes methods for the removal of such groups.
  • esters of formula (VI) are first hydrolysed to their corresponding acids, for example by treatment with a strong base (e.g. sodium hydroxide), in the present of a solvent (e.g. ethanol) and at elevated temperature.
  • a strong base e.g. sodium hydroxide
  • a solvent e.g. ethanol
  • a halogenating agent conveniently at ambient temperature and in a solvent (e.g. chlorinated hydrocarbon), under which conditions the acid undergoes both halogenation and decarboxylation.
  • the halogenating agent is a brominating agent, such as bromine in the presence of a strong acid (e.g. hydrobromic acid in acetic acid) or N-bromosuccinimide, to yield the corresponding compound of formula (II) wherein Hal is bromine.
  • Esters of formula (VII) may be prepared by reacting a compound of formula (VIII) with an aminopyridazinium complex of formula (IX) under conventional conditions. Conveniently the reaction is effected in the presence of a base, such as potassium carbonate, a solvent, such as N,N-dimethylformamide and at ambient temperature.
  • a base such as potassium carbonate
  • a solvent such as N,N-dimethylformamide
  • compounds of the invention are isolated following work-up in the form of the free base.
  • Pharmaceutically acceptable acid addition salts of the compounds of the invention may be prepared using conventional means.
  • Solvates (e.g. hydrates) of a compound of the invention may be formed during the work-up procedure of one of the aforementioned process steps.
  • 1,8-Diazabicyclo[5.4.0]undec-7-ene (3.39 ml) was added to a mixture of 3-(4-fluorophenyl)-prop-2-ynoic acid methyl ester (3.36 g) and 1-amino-3-methoxy-pyridazin-1-ium mesitylene sulphonate 1 (6.1419 g) in acetonitrile (125 ml) and the mixture was stirred at ambient temperature for 48 hours. During the first 2 hours a stream of air was passed through the reaction.
  • Diazabicyclo[5.4.0]undec-7-ene (22.76 ml, 2 eq) was added dropwise to a solution of methyl 3-(4-methoxy-phenyl)-prop-2-ynoic acid 1 (14.46 g, 76 mM) and 1-amino pyridazinium iodide 2 (2 eq) in acetonitrile under nitrogen and stirred for 6 h. Purification by chromatography on silica gel eluting with toluene, then toluene:ethyl acetate (9:1) gave the title compound (2.76 g) as a brown solid.
  • Solid t-butoxycarbonyl-O-mesitylenesulfonylhydroxylamine 1 (7.8 g) was added portionwise with stirring to TFA (25 ml) over 10 min then stirred for a further 20 minutes.
  • the solution was poured onto ice ( ⁇ 200 ml) and left until the ice melted.
  • the resulting white solid was filtered off, washed with water, and dissolved in DME (100 ml).
  • the solution was dried over 4 A mol. sieves for 1.5 hours, filtered then added to a solution of 3-methylthio-pyridazine 2 (2.6 g) in dichloromethane (35 ml) and the reaction stirred at room temperature for 20 h.
  • the intermediate salt was isolated by filtration as light brown crystals (3.87 g), suspended in acetonitrile (100 ml) and methyl 3-(4-fluoro-phenyl)-prop-2-ynoic acid (2.02 g) added. 1,8-Diazabicyclo[5.4.0]undec-7-ene (2.1 ml) was added dropwise and the reaction was stirred at room temperature for 20 hours. The resulting crystalline precipitate was filtered off, washed and dried (770 mg). Concentration of the filtrate gave a second crop (430 mg). The residues were partioned between water and ethyl acetate (100 ml each) and the aqueous layer was extracted with ethyl acetate (20 ml).
  • Diazabicyclo[5.4.0]undec-7-ene (1.47 ml, 2 eq) was added dropwise to a solution of methyl 3-(4-ethoxy-phenyl)-prop-2-ynoic acid (1.0 g) and 1-amino pyridazinium iodide 2 (2.19 g) in acetonitrile (10 ml) under nitrogen and stirred for 5 h. Concentration and aqueous workup gave the title compound (1.2 g) as a sticky brown solid.
  • 1,8-Diazabicyclo[5.4.0]undec-7-ene (5 ml) was added to a stirred, chilled, mixture of (3-fluoro-phenyl)-propynoic acid methyl ester (2.67 g) and 1-amino-3-methoxy-pyridazin-1-ium mesitylene sulphonate (4.89 g) in acetonitrile (80 ml) and the mixture was stirred at 0° for 1 hour then at ambient temperature for 18 hours. The mixture was concentrated in vacuo, and partitioned between ethyl acetate (150 ml) and water (150 ml).
  • COS cells which had been stably transfected with cDNA for human COX-1 and human COX-2. 24 Hours prior to experiment, COS cells were transferred from the 175 cm 2 flasks in which they were grown, onto 24-well cell culture plates using the following procedure.
  • the incubation medium was completely removed from the 24-well cell culture plates and replaced with 250 ⁇ l fresh DMEM (37° C.).
  • the test compounds were made up to 250 ⁇ the required test concentration in DMSO and were added to the wells in a volume of 1 ⁇ l. Plates were then mixed gently by swirling and then placed in an incubator for 1 hour (37° C., 95% air/5% CO 2 ). Following the incubation period, 10 ⁇ l of arachidonic acid (750 ⁇ M) was added to each well to give a final arachidonic acid concentration of 30 ⁇ M.
  • IC 50 value which is defined as the concentration of the compound required to inhibit the PGE2 release from the cells by 50%.
  • the selectivity ratio of inhibition of COX-1 versus COX-2 was calculated by comparing respective IC 50 values.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

The invention provides a pharmaceutical composition comprising a compound of formula (I)
Figure US20050113377A1-20050526-C00001
or a pharmaceutically acceptable salt, solvate, ester or salt or solvate of such ester, of a compound of formula (I) in which:
    • R0 is halogen, C1-6alkyl, C1-6alkoxy, C1-6alkoxy substituted by one or more fluorine atoms, or O(CH2)nNR4R5;
    • R1 and R2 are independently selected from H, C1-6alkyl, C1-6alkyl substituted by one or more fluorine atoms, C1-6alkoxy, C1-6hydroxyalkyl, SC1-6alkyl, C(O)H, C(O)C1-6alkyl, C1-6alkylsulphonyl, C1-6alkoxy substituted by one or more fluorine atoms, O(CH2)nCO2C1-6alkyl, O(CH2)nSC1-6alkyl, (CH2)nNR4R5, (CH2)nSC1-6alkyl or C(O)NR4R5; with the proviso that when R0 is at the 4-position and is halogen, at least one of R1 and R2 is C1-6alkylsulphonyl, C1-6alkoxy substituted by one or more fluorine atoms, O(CH2)nCO2C1-6alkyl, O(CH2)nSC1-6alkyl, (CH2)nNR4R5 or (CH2)nSC1-6alkyl, C(O)NR4R5;
    • R3 is C1-6alkyl or NH2;
    • R4 and R5 are independently selected from H and C1-6alkyl or, together with the nitrogen atom to which they are attached, form a 4-8 membered saturated ring; and n is 1-4; and an inhibitor of the release, or action, of tumour necrosis factor α.

Description

  • This invention relates to pyrazolo[1,5-b]pyridazine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.
  • The enzyme cyclooxygenase (COX) has recently been discovered to exist in two isoforms, COX-1 and COX-2. COX-1 corresponds to the originally identified constitutive enzyme while COX-2 is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors. Prostaglandins generated by the action of COX have both physiological and pathological roles. It is generally believed that COX-1 is responsible for the important physiological functions such as maintenance of gastrointestinal integrity and renal blood flow. In contrast the inducible form, COX-2, is believed to be responsible for the pathological effects of prostaglandins where rapid induction of the enzyme occurs in response to such agents as inflammatory agents, hormones, growth factors and cytokines. A selective inhibitor of COX-2 would therefore have anti-inflammatory, anti-pyretic and analgesic properties, without the potential side effects associated with inhibition of COX-1. We have now found a novel group of compounds which are both potent and selective inhibitors of COX-2.
  • The invention thus provides the compounds of formula (I)
    Figure US20050113377A1-20050526-C00002

    and pharmaceutically acceptable derivatives thereof in which:
    • R0 is halogen, C1-6alkyl, C1-6alkoxy, C1-6alkoxy substituted by one or more fluorine atoms, or O(CH2)nNR4R5;
    • R1 and R2 are independently selected from H, C1-6alkyl, C1-6alkyl substituted by one or more fluorine atoms, C1-6alkoxy, C1-6hydroxyalkyl, SC1-6alkyl, C(O)H, C(O)C1-6alkyl, C1-6alkylsulphonyl, C1-6alkoxy substituted by one or more fluorine atoms, O(CH2)nCO2C1-6alkyl, O(CH2)nSC1-6alkyl, (CH2)nNR4R5, (CH2)nSC1-6alkyl or C(O)NR4R5; with the proviso that when R0 is at the 4-position and is halogen, at least one of R1 and R2 is C1-6alkylsulphonyl, C1-6alkoxy substituted by one or more fluorine atoms, O(CH2)nCO2C1-6alkyl, O(CH2)nSC1-6alkyl, (CH2)nNR4R5 or (CH2)nSC1-6alkyl, C(O)NR4R5;
    • R3 is C1-6alkyl or NH2;
    • R4 and R5 are independently selected from H, or C1-6alkyl or, together with the nitrogen atom to which they are attached, form a 4-8 membered saturated ring; and
    • n is 1-4.
  • By pharmaceutically acceptable derivative is meant any pharmaceutically acceptable salt, solvate or ester, or salt or solvate of such ester, of the compounds of formula (I), or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.
  • It will be appreciated that, for pharmaceutical use, the salts referred to above will be the physiologically acceptable salts, but other salts may find use, for example in the preparation of compounds of formula (I) and the physiologically acceptable salts thereof.
  • Suitable pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts formed with inorganic or organic acids, preferably inorganic acids, e.g. hydrochlorides, hydrobromides and sulphates.
  • The term halogen is used to represent fluorine, chlorine, bromine or iodine.
  • The term ‘alkyl’ as a group or part of a group means a straight or branched chain alkyl group, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl or t-butyl group.
  • Preferably, R0 is at the 3- or 4-position of the phenyl ring, as defined in formula (I).
  • Preferably, R0 is at the 6-position of the pyridazine ring, as defined in formula (I).
  • Preferably, R0 is F, C1-3alkyl, C1-3alkoxy, C1-3alkoxy substituted by one or more fluorine atoms, or O(CH2)1-3NR4R5. More preferably R0 is F, C1-3alkoxy or C1-3alkoxy substituted by one or more fluorine atoms.
  • Preferably, R1 is C1-4alkylsulphonyl, C1-4alkoxy substituted by one or more fluorine atoms, O(CH2)1-3CO2C1-4alkyl, O(CH2)1-3SC1-4alkyl, (CH2)1 NR4R5, (CH2)1-3SC1-4alkyl or C(O)NR4R5 or, when R0 is C1-6alkyl, C1-4alkoxy, O(CH2)nNR4R5, may also be H. More preferably R1 is C1-4alkylsulphonyl, C1-4alkoxy substituted by one or more fluorine atoms or, when R0 is C1-6alkyl, C1-6alkoxy, C1-6alkoxy substituted by one or more fluorine atoms, or O(CH2)nNR4R5, may also be H.
  • Preferably, R2 is H.
  • Preferably, R3 is methyl or NH2.
  • Preferably R4 and R5 are independently C1-3alkyl or, together with the nitrogen atom to which they are attached, form a 5-6 membered saturated ring.
  • Preferably, n is 1-3, more preferably 1 or 2.
  • Within the invention there is provided one group of compounds of formula (I) (group A) wherein: R0 is F, C1-3alkyl, C1-3alkoxy, C1-3alkoxy substituted by one or more fluorine atoms, or O(CH2)nNR4R5; R1 is C1-4alkylsulphonyl, C1-4alkoxy substituted by one or more fluorine atoms, O(CH2)nCO2C1-4alkyl, O(CH2)nSC1-4alkyl, (CH2)nNR4R5, (CH2)nSC1-4alkyl or C(O)NR4R5 or, when R0 is C1-3alkyl, C1-3alkoxy, C1-3alkoxy substituted by one or more fluorine atoms, or O(CH2)nNR4R5, may also be H; R2 is H; R3 is methyl or NH2; R4 and R5 are independently C1-3alkyl or, together with the nitrogen atom to which they are attached, form a 5-6 membered saturated ring; and n is 1-3.
  • Within group A, there is provided another group of compounds (group A1) wherein R0 is F, methyl, C1-2alkoxy, OCHF2, or O(CH2)nNR4R5; R1 is methylsulphonyl, OCHF2, O(CH2)nCO2C1-4alkyl, O(CH2)nSCH3, (CH2)nNR4R5, (CH2)nSCH3 or C(O)NR4R5 or, when R0 is methyl, C1-2alkoxy, OCHF2, or O(CH2)nN(CH3)2, may also be H; R2 is H; R3 is methyl or NH2; R4 and R5 are both methyl or, together with the nitrogen atom to which they are attached, form a 5-6 membered saturated ring; and n is 1-2.
  • Within group A, there is provided a further group of compounds (group A2) wherein R0 is F, C1-3alkoxy or C1-3alkoxy substituted by one or more fluorine atoms; R1 is C1-4alkylsulphonyl, C1-4alkoxy substituted by one or more fluorine atoms or, when R0 C1-3alkoxy or C1-3alkoxy substituted by one or more fluorine atoms, may also be H; R2 is H; and R3 is methyl or NH2.
  • Within groups A, A1 and A2, R0 is preferably at the 3- or 4-position of the phenyl ring and R2 is preferably at the 6-position of the pyridazine ring.
  • It is to be understood that the present invention encompasses all isomers of the compounds of formula (I) and their pharmaceutically acceptable derivatives, including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures).
  • Particularly preferred compounds of the invention are:
    • 3-(4-methanesulfonyl-phenyl)-2-(4-methoxy-phenyl)-pyrazolo[1,5-b]pyridazine;
    • 6-difluoromethoxy-2-(4-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
    • 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)pyrazolo[1,5-b]pyridazine;
    • 2-(4-fluoro-phenyl)-6-methanesulfonyl-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
    • 2-(4-difluoromethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
    • 4-[2-(4-ethoxy-phenyl)-pyrazolo[1,5-b]pyridazin-3-yl]-benzenesulfonamide;
    • 6-difluoromethoxy-2-(3-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
      and pharmaceutically acceptable derivatives thereof.
  • Compounds of the invention are potent and selective inhibitors of COX-2. This activity is illustrated by their ability to selectively inhibit COX-2 over COX-1.
  • In view of their selective COX-2 inhibitory activity, the compounds of the present invention are of interest for use in human and veterinary medicine, particularly in the treatment of the pain (both chronic and acute), fever and inflammation of a variety of conditions and diseases. Such conditions and diseases are well known in the art and include rheumatic fever; symptoms associated with influenza or other viral infections, such as the common cold; lower back and neck pain; headache; toothache; sprains and strains; myositis; neuralgia; synovitis; arthritis, including rheumatoid arthritis; degenerative joint diseases, including osteoarthritis; gout and ankylosing spondylitis; tendinitis; bursitis; skin related conditions, such as psoriasis, eczema, burns and dermatitis; injuries, such as sports injuries and those arising from surgical and dental procedures.
  • The compounds of the invention may also be useful for the treatment of other conditions mediated by selective inhibition of COX-2.
  • For example, the compounds of the invention may inhibit cellular and neoplastic transformation and metastatic tumour growth and hence be useful in the treatment of certain cancerous diseases, such as colonic cancer.
  • Compounds of the invention may also prevent neuronal injury by inhibiting the generation of neuronal free radicals (and hence oxidative stress) and therefore may be of use in the treatment of stroke; epilepsy; and epileptic seizures (including grand mal, petit mal, myoclonic epilepsy and partial seizures).
  • Compounds of the invention also inhibit prostanoid-induced smooth muscle contraction and hence may be of use in the treatment of dysmenorrhoea and premature labour.
  • Compounds of the invention inhibit inflammatory processes and therefore may be of use in the treatment of asthma, allergic rhinitis and respiratory distress syndrome; gastrointestinal conditions such as inflammatory bowel disease, Chron's disease, gastritis, irritable bowel syndrome and ulcerative colitis; and the inflammation in such diseases as vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, type I diabetes, myasthenia gravis, multiple sclerosis, sorcoidosis, nephrotic syndrome, Bechet's syndrome, polymyositis, gingivitis, conjunctivitis and myocardial ischemia.
  • Compounds of the invention may also be useful in the treatment of ophthalmic diseases such as retinitis, retinopathies, uveitis and of acute injury to the eye tissue.
  • Compounds of the invention may also be useful for the treatment of cognitive disorders such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntington's chorea, Parkinson's disease and Creutzfeldt-Jakob disease), and vascular dementia (including multi-infarct dementia), as well as dementia associated with intracranial space occupying lesions, trauma, infections and related conditions (including HIV infection), metabolism, toxins, anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment.
  • According to a further aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in human or veterinary medicine.
  • According to another aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by selective inhibition of COX-2.
  • According to a further aspect of the invention, we provide a method of treating a human or animal subject suffering from a condition which is mediated by selective inhibition of COX-2 which comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative.
  • According to another aspect of the invention, we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a therapeutic agent for the treatment of a condition which is mediated by selective inhibition of COX-2, such as an inflammatory disorder.
  • According to a further aspect of the invention, we provide a method of treating a human or animal subject suffering from an inflammatory disorder, which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • It is to be understood that reference to treatment includes both treatment of established symptoms and prophylactic treatment, unless explicitly stated otherwise.
  • It will be appreciated that the compounds of the invention may advantageously be used in conjunction with one or more other therapeutic agents. Examples of suitable agents for adjunctive therapy include pain relievers such as a glycine antagonist, a sodium channel inhibitor (e.g. lamotrigine), a substance P antagonist (e.g. an NK1 antagonist), acetaminophen or phenacetin; a matrix metalloproteinase inhibitor; a nitric oxide synthase (NOS) inhibitor (e.g. an iNOS or an nNOS inhibitor); an inhibitor of the release, or action, of tumour necrosis factor α; an antibody therapy (e.g. a monoclonal antibody therapy); a stimulant, including caffeine; an H2-antagonist, such as ranitidine; a proton pump inhibitor, such as omeprazole; an antacid, such as aluminium or magnesium hydroxide; an antiflatulent, such as simethicone; a decongestant, such as phenylephrine, phenylpropanolamine, pseudoephedrine, oxymetazoline, epinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antitussive, such as codeine, hydrocodone, carmiphen, carbetapentane, or dextramethorphan; a diuretic; or a sedating or non-sedating antihistamine. It is to be understood that the present invention covers the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in combination with one or more other therapeutic agents.
  • The compounds of formula (I) and their pharmaceutically acceptable derivatives are conveniently administered in the form of pharmaceutical compositions. Thus, in another aspect of the invention, we provide a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof adapted for use in human or veterinary medicine. Such compositions may conveniently be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or excipients.
  • The compounds of formula (I) and their pharmaceutically acceptable derivatives may be formulated for administration in any suitable manner. They may, for example, be formulated for topical administration or administration by inhalation or, more preferably, for oral, transdermal or parenteral administration. The pharmaceutical composition may be in a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable derivatives.
  • For oral administration, the pharmaceutical composition may take the form of, for example, tablets (including sub-lingual tablets), capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.
  • For transdermal administration, the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.
  • For parenteral administration, the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravascularly or subcutaneously). The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. For administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably with an added preservative.
  • Alternatively for parenteral administration the active ingredient may be in powder form for reconstitution with a suitable vehicle.
  • The compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • As stated above, the compounds of the invention may also be used in combination with other therapeutic agents. The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent.
  • The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
  • When a compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same disease state the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
  • A proposed daily dosage of a compound of formula (I) for the treatment of man is 0.01 mg/kg to 500 mg/kg, such as 0.05 mg/kg to 100 mg/kg, e.g. 0.1 mg/kg to 50 mg/kg, which may be conveniently administered in 1 to 4 doses. The precise dose employed will depend on the age and condition of the patient and on the route of administration. Thus, for example, a daily dose of 0.25 mg/kg to 10 mg/kg may be suitable for systemic administration.
  • Compounds of formula (I) and pharmaceutically acceptable derivatives thereof may be prepared by any method known in the art for the preparation of compounds of analogous structure.
  • Suitable methods for the preparation of compounds of formula (I) and pharmaceutically acceptable derivatives thereof are described below. In the formulae that follow R0 to R5 and n are as defined in formula (I) above unless otherwise stated; Hal is a halogen, such as Br or I; X is a counterion, such as I; and alkyl is as previously defined.
  • Thus according to a first process (A), compounds of formula (I) may be prepared by reacting a compound of formula (II)
    Figure US20050113377A1-20050526-C00003

    or a protected derivative thereof with a boronic acid of formula (III)
    Figure US20050113377A1-20050526-C00004

    or a suitable derivative thereof in the presence of a suitable transition metal catalyst. Suitable derivatives of formula (III) include boronic acid esters, such as those described in R. Miyaura et al, J. Org. Chem., 1995, 60, 7508-7510. Conveniently, the reaction is carried out in a solvent, such as an ether (e.g. 1,2 dimethoxyethane); in the presence of a base, such as an inorganic base (e.g. sodium carbonate); and employing a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0).
  • According to a another process (B), compounds of formula (I) wherein R3 is C1-6alkyl may be prepared by oxidising a compound of formula (IV)
    Figure US20050113377A1-20050526-C00005

    or a protected derivative thereof under conventional conditions. Conveniently the oxidation is effected using a monopersulfate compound, such as potassium peroxymonosulfate (known as Oxone™) and the reaction is carried out in a solvent, such as an aqueous alcohol, (e.g. aqueous methanol), and at between −78° C. and ambient temperature.
  • According to a another process (C), compounds of formula (I) wherein R1 is C1-6alkylsulphonyl may be prepared by oxidising a compound of formula (V)
    Figure US20050113377A1-20050526-C00006

    or a protected derivative thereof under conventional conditions. Conveniently the oxidation is effected in the manner described just above for process (B).
  • According to a another process (D), compounds of formula (I) wherein R1 is C1-6alkoxy substituted by one or more fluorine atoms may be prepared by reacting an alcohol of formula (VI)
    Figure US20050113377A1-20050526-C00007

    or a protected derivative thereof with a halofluoroalkane under conventional conditions. Conveniently the reaction is effected in a solvent, such as a polar solvent (e.g. N,N-dimethylformamide), in the presence of a strong base, such as an inorganic hydride (e.g. sodium hydride), at about ambient temperature and using the appropriate bromofluoroalkane to give the desired compound of formula (I).
  • According to another process (E) compounds of formula (I) may be prepared by interconversion, utilising other compounds of formula (I) as precursors. The following procedures are illustrative of suitable interconversions.
  • Compounds of formula (I) wherein R1 or R2 represent C1-4alkyl substituted by one or more fluorine atoms may be prepared from the appropriate compound of formula (I) wherein R1 or R2 is C1-6hydroxyalkyl, C(O)H or C(O)C1-6alkyl, by treatment with a suitable source of fluorine. Suitable sources of fluorine include, for example, diethylaminosulphur trifluoride. Conveniently the reaction is effected in the presence of a solvent, such as a halogenated hydrocarbon (e.g. dichloromethane), and at reduced temperature, such as −78° C.
  • Compounds of formula (I) wherein R1 or R2 represent C(O)H may be prepared from the corresponding compound of formula (I) wherein R1 or R2 represent CH2OH by oxidation. Suitable oxidising agents include, for example, manganese (IV) oxide. Conveniently the oxidation is effected in the presence of a solvent, such as a halogenated hydrocarbon (e.g. chloroform), and at elevated temperature (e.g. reflux).
  • Compounds of formula (I) wherein R1 or R2 represent C1-6hydroxyalkyl, and wherein the hydroxy group is attached to the carbon linked to the pyridazine ring, may be prepared by reduction of the compound of formula (I) wherein R1 or R2 represent the corresponding aldehyde or ketone. Suitable reducing agents include hydride reducing agents, such as diisobutylaluminium hydride.
  • Conveniently the reduction is effected in the presence of a solvent, such as a halogenated hydrocarbon (e.g. dichloromethane), and at reduced temperature, such as −78° C.
  • As will be appreciated by those skilled in the art it may be necessary or desirable at any stage in the synthesis of compounds of formula (I) to protect one or more sensitive groups in the molecule so as to prevent undesirable side reactions.
  • Another process (F) for preparing compounds of formula (I) thus comprises deprotecting protected derivatives of compounds of formula (I).
  • The protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See, for example, those described in ‘Protective Groups in Organic Synthesis’ by Theodora W. Greene and Peter G. M. Wuts, second edition, (John Wiley and Sons, 1991), which also describes methods for the removal of such groups.
  • Compounds of formula (II) may be prepared by halogenating compounds of formula (VII)
    Figure US20050113377A1-20050526-C00008

    by conventional means.
  • Thus esters of formula (VI) are first hydrolysed to their corresponding acids, for example by treatment with a strong base (e.g. sodium hydroxide), in the present of a solvent (e.g. ethanol) and at elevated temperature. The corresponding acid is then treated with a halogenating agent, conveniently at ambient temperature and in a solvent (e.g. chlorinated hydrocarbon), under which conditions the acid undergoes both halogenation and decarboxylation. Conveniently, the halogenating agent is a brominating agent, such as bromine in the presence of a strong acid (e.g. hydrobromic acid in acetic acid) or N-bromosuccinimide, to yield the corresponding compound of formula (II) wherein Hal is bromine.
  • Esters of formula (VII) may be prepared by reacting a compound of formula (VIII)
    Figure US20050113377A1-20050526-C00009

    with an aminopyridazinium complex of formula (IX)
    Figure US20050113377A1-20050526-C00010

    under conventional conditions. Conveniently the reaction is effected in the presence of a base, such as potassium carbonate, a solvent, such as N,N-dimethylformamide and at ambient temperature.
  • Boronic acids of formula (III) are either known compounds or may be prepared by literature methods such as those described in, for example, EPA publication No. 533268.
  • Compounds of formulae (IV), (V) and (VI) may be prepared by methods analogous to those described for the preparation of the compound of formula (I) from compounds of formula (II).
  • Compounds of formula (VIII) are either known compounds or may be prepared by literature methods such as those described in, for example, D H Wadsworth et al, J Org Chem, (1987), 52(16), 3662-8 and J. Morris and D. G. Wishka, Synthesis (1994), (1), 43-6.
  • Compounds of formula (IX) are either known compounds or may be prepared by literature methods such as those described in, for example, Y Kobayashi et al., Chem Pharm Bull, (1971), 19(10), 2106-15; T. Tsuchiya, J. Kurita and K. Takayama, Chem. Pharm. Bull. 28(9) 2676-2681 (1980) and K Novitskii et al., Khim Geterotskil Soedin, 1970 2, 57-62.
  • Certain intermediates described above are novel compounds, and it is to be understood that all novel intermediates herein form further aspects of the present invention. Compounds of formula (II) are key intermediates and represent a particular aspect of the present invention.
  • Conveniently, compounds of the invention are isolated following work-up in the form of the free base. Pharmaceutically acceptable acid addition salts of the compounds of the invention may be prepared using conventional means.
  • Solvates (e.g. hydrates) of a compound of the invention may be formed during the work-up procedure of one of the aforementioned process steps.
  • The following Examples illustrate the invention but do not limit the invention in any way. All temperatures are in ° C. Flash column chromatography was carried out using Merck 9385 silica. Thin layer chromatography (Tlc) was carried out on silica plates. NMR was carried out on a Brucker 250 MHz spectrometer. Chemical shifts are given, with respect to tetramethylsilane as internal chemical shift reference, in δ ppm. The following abbreviations are used: Me=methyl, s=singlet, d=doublet, t=triplet and m=multiplet.
  • EXAMPLE 1 6-Difluoromethoxy-2-(4-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine (i) 6-Methoxy-2-(4-fluoro-phenyl-pyrazolo[1,5-b]pyridazine-3-carboxylic Acid Methyl Ester
  • 1,8-Diazabicyclo[5.4.0]undec-7-ene (3.39 ml) was added to a mixture of 3-(4-fluorophenyl)-prop-2-ynoic acid methyl ester (3.36 g) and 1-amino-3-methoxy-pyridazin-1-ium mesitylene sulphonate1 (6.1419 g) in acetonitrile (125 ml) and the mixture was stirred at ambient temperature for 48 hours. During the first 2 hours a stream of air was passed through the reaction. The mixture was concentrated in vacuo, dissolved in ethyl acetate (150 ml), washed with water (3×25 ml), dried (MgSO4), filtered and evaporated in vacuo to give the title compound as a brown solid (4.77 g).
  • 1H NMR (CDCl3): 8.4 (d, 1H, J=10 Hz) 7.85-7.90 (m, 2H) 7.1-7.2 (m, 2H) 6.9-7.0 (d, 1H, J=10 Hz) 4.1 (s, 3H) 3.9 (s, 3H)
  • MH+ 302
  • Ref:1 T. Tsuchiya, J. Kurita and K. Takayama, Chem. Pharm. Bull. 28(9) 2676-2681 (1980).
  • (ii) 6-Methoxy-2-(4-fluoro-phenyl-pyrazolo[1,5-b]pyridazine-3-carboxylic Acid
  • A mixture of 6-methoxy-2-(4-fluoro-phenyl-pyrazolo[1,5-b]pyridazine-3-carboxylic acid methyl ester (4.469 g), 2N sodium hydroxide (50 ml) and methanol (90 ml) was heated at reflux for 2 hours. The cooled solution was added to 2N hydrochloric acid (200 ml) and the title compound was isolated by filtration as a beige solid (3.639 g).
  • 1H NMR (DMSO-d6): 12.8 (br. s, 1H) 8.4 (d, 1H, J=10 Hz) 7.8-7.9 (m, 2H) 7.21-7.32 (m, 2H) 7.15-7.2 (d, 1H, J=10 Hz) 4.0 (s, 3H)
  • MH+ 288
  • (iii) 2-(4-Fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-6-methoxy-pyrazolo[1,5-b]pyridazine
  • A mixture of 6-methoxy-2-(4-fluoro-phenyl-pyrazolo[1,5-b]pyridazine-3-carboxylic acid (869 mg) and sodium bicarbonate (756 mg) in dimethylformamide (10 ml) was treated with N-bromosuccinimide (587 mg) and stirred at ambient temperature for 1 hour, then added to water (50 ml) and extracted with ethyl acetate (3×50 ml), dried (MgSO4), and evaporated in vacuo. The resulting brown solid (1.612 g) was dissolved in 1,2 dimethoxyethane (20 ml). 2N Aqueous sodium carbonate solution (10 ml) was added together with 4-(methanesulphonyl)phenyl boronic acid (660 mg) and tetrakis(triphenylphosphine)palladium (0) (100 mg) and the mixture was heated at reflux for 20 hours. The reaction was poured into water (50 ml), extracted with dichloromethane (3×100 ml). The combined organic extracts were dried (MgSO4) and evaporated in vacuo to give a brown solid (1.116 g) which was purified by flash column chromatography on silica, eluting with cyclohexane/ethyl acetate (4:1 then 2:1), to give the title compound as a yellow solid (390 mg).
  • Tic, SiO2, Rf 0.3 (1:1 cyclohexane/ethyl acetate), detection UV
  • MH+ 398
  • (iv) 2-(4-Fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazin-6-ol
  • A mixture of 2-(4-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-6-methoxy-pyrazolo[1,5-b]pyridazine (321 mg) and pyridine hydrochloride (1.4 g) was heated to and at 200° C. in a sealed vessel (Reactivial™) for 3 hours. The cooled reaction was poured into water (20 ml), and extracted with ethyl acetate (3×30 ml). The combined organic extracts dried (MgSO4), filtered and evaporated in vacuo to give a solid which was triturated with diethyl ether to give the title compound as a beige solid (119 mg).
  • Tlc, SiO2, Rf 0.07 (1:2 cyclohexane/ethyl acetate), detection UV.
  • MH+ 384
  • (v) 6-Difluoromethoxy-2-(4-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine
  • A solution of 2-(4-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazin-6-ol (0.2 g) in anhydrous dimethyl formamide (5 ml) was treated with sodium hydride (0.046 g, 60% dispersion in mineral oil), after effervescence ceased a stream of bromodifluoromethane gas was passed through the mixture at ambient temperature for 30 minutes. The reaction mixture was then poured into water (50 ml) and extracted with ethyl acetate (50 ml), the organic extract was washed with water (3×50 ml), dried and concentrated in vacuo. The residue was purified by chromatography to give the title compound as a white solid (0.17 g).
  • MH+ =434
  • 1HNMR(CDCl3):δ8.05-8.0(d,J=10 HZ,2H) 8.0-7.95(d,J=10 HZ,1H) 7.6-7.5(m,4H) 7.8-7.2(t,J=70 HZ,1H) 7.1-7.05(t,J=11 HZ,2H) 6.9-6.85(d,J=10 HZ,1H) 3.15(s,3H)
  • Tlc, SiO2, Rf 0.35(ethyl acetate/cyclohexane(1/1))
  • EXAMPLE 2 3-(4-Methanesulfonyl-phenyl)-2-(4-methoxy-phenyl)-pyrazolo[1,5-b]pyridazine (i) 2-(4-Methoxy-phenyl)-pyrazolo[1,5-b]pyridazine-3-carboxylic Acid Methyl Ester
  • Diazabicyclo[5.4.0]undec-7-ene (22.76 ml, 2 eq) was added dropwise to a solution of methyl 3-(4-methoxy-phenyl)-prop-2-ynoic acid1 (14.46 g, 76 mM) and 1-amino pyridazinium iodide2 (2 eq) in acetonitrile under nitrogen and stirred for 6 h. Purification by chromatography on silica gel eluting with toluene, then toluene:ethyl acetate (9:1) gave the title compound (2.76 g) as a brown solid.
  • MH+ 284
  • 1H NMR (CDCl3) δ 3.87 (3H, s) 3.9 (3H, s) 7.0 (2H, d, J=9 Hz) 7.25 (1H, dd, J=9 & 4 Hz) 7.90 (2H, d, J=9 Hz) 8.45 (1H, dd, J=4 & 2 Hz) 8.55 (1H, dd, J=9 & 2 Hz)
  • Ref: 1 J. Morris and D. G. Wishka, Synthesis (1994), (1), 43-6
  • Ref: 2 Kobayashi et al Chem.Pharm.Bull. (1971), 19 (10), 2106-15
  • (ii) 3-(4-Methanesulfonyl-phenyl)-2-(4-methoxy-phenyl)-pyrazolo[1,5-b]pyridazine
  • A mixture of 2-(4-methoxy-phenyl)-pyrazolo[1,5-b]pyridazine-3-carboxylic acid methyl ester (2.76 g) and aq. sodium hydroxide (2N, 30 ml) in ethanol (30 ml) was refluxed under nitrogen for 2 h. The cooled mixture was acidified with hydrochloric acid (2N) and the resulting white solid (2.53 g) isolated by filtration. This solid was dissolved in DMF and sodium bicarbonate (2.67 g, 3.3 eq) added, followed by N-bromosuccinimide (1.88 g, 1.1 eq) portionwise. After stirring for 1 h under nitrogen, water was added and extracted into ethyl acetate (2×25 ml). The dried organic phase was concentrated and the residue taken up in DME (60 ml). Aqueous sodium carbonate (2N, 15 ml) was added, followed by 4-methanesulfonyl-phenylboronic acid (3.12 g) and tetrakis(triphenylphosphine)palladium(0) (250 mg). The mixture was heated at reflux under nitrogen for 18 h, cooled, poured into water and extracted into ethyl acetate (2×25 ml). The combined organic phases were dried and concentrated onto silica gel. Chromatography on silica gel eluting with toluene:ethyl acetate (8:1) gave, on concentration, the title compound (3.58 g) as a cream solid.
  • MH+ 380
  • 1H NMR (DMSO) δ 3.25 (3H, s) 3.75 (3H, s) 6.95 (2H, d, J=8.5 Hz) 7.25 (1H, dd, J=9 & 5 Hz) 7.45 (2H, d, J=8.5 Hz) 7.60 (2H, d, J=8 Hz) 7.9 (2H, d, J=8.5 Hz) 8.15 (1H, dd, J=9&2 Hz) 8.49 (1H, dd, J=5&2 Hz)
  • EXAMPLE 3 2-(4-Ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine (i) 4-[3-(4-Methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazin-2-yl]-phenol
  • Boron tribromide (1 M solution in CH2Cl2, 2.1 eq) was added to 3-(4-methanesulfonyl-phenyl)-2-(4-methoxy-phenyl)-pyrazolo[1,5-b]pyridazine (3.58 g) in CH2Cl2 at −70°. The mixture was stirred for 10 min then warmed to 0° and stirred at 0° overnight. The reaction mixture was made alkaline with potassium carbonate then acidified with hydrochloric acid (2M), poured into water and extracted into CH2Cl2. The organic phase was dried, filtered and concentrated to give the title compound (1.87 g) as a yellow solid.
  • MH+ 366
  • 1H NMR (DMSO) δ 3.30 (3H, s) 6.80 (2H, d, J=8.5 Hz) 7.30 (1H, dd, J=9 & 5 Hz) 7.35 (2H, d, J=8.5 Hz) 7.60 (2H, d, J=8 Hz) 8.0 (2H, d, J=8.5 Hz) 8.20 (1H, dd, J=9& 2 Hz) 8.55 (1H, dd, J=5& 2 Hz) 9.75 (1H, s)
  • (ii) 2-(4-Ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine
  • 4-[3-(4-Methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazin-2-yl]-phenol (663 mg, 1.82), iodoethane (1 eq) and potassium carbonate (2 eq) in acetonitrile (30 ml) were heated at reflux under nitrogen for 18 h. The cooled reaction mixture was partitioned between water (30 ml) and ethyl acetate (30 ml). The organic phase was collected, dried and purified by chromatography to give the title compound (547 mg) as a cream foam.
  • MH+ 394
  • 1H NMR (DMSO) δ 1.45 (3H, t, J=7 Hz) 3.10 (3H, s) 4.1 (2H, q, J=7 Hz) 6.87 (2H, d, J=9 Hz) 7.08 (1H, dd, J=9 & 5 Hz) 7.55 (4H, t, J=9 Hz) 7.92 (1H, dd, J=9 &2 Hz) 7.95 (2H, d, J=9 Hz) 8.20 (1H, dd, J=9& 2 Hz) 8.32 (1H, dd, J=5& 2 Hz)
  • EXAMPLE 4 2-(4-Fluoro-phenyl)-6-methanesulfonyl-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine (i) 2-(4-Fluoro-phenyl)-6-methylsulfanyl-pyrazolo[1,5-b]pyridazine-3-carboxylic Acid Methyl Ester
  • Solid t-butoxycarbonyl-O-mesitylenesulfonylhydroxylamine1 (7.8 g) was added portionwise with stirring to TFA (25 ml) over 10 min then stirred for a further 20 minutes. The solution was poured onto ice (˜200 ml) and left until the ice melted. The resulting white solid was filtered off, washed with water, and dissolved in DME (100 ml). The solution was dried over 4 A mol. sieves for 1.5 hours, filtered then added to a solution of 3-methylthio-pyridazine2 (2.6 g) in dichloromethane (35 ml) and the reaction stirred at room temperature for 20 h. The intermediate salt was isolated by filtration as light brown crystals (3.87 g), suspended in acetonitrile (100 ml) and methyl 3-(4-fluoro-phenyl)-prop-2-ynoic acid (2.02 g) added. 1,8-Diazabicyclo[5.4.0]undec-7-ene (2.1 ml) was added dropwise and the reaction was stirred at room temperature for 20 hours. The resulting crystalline precipitate was filtered off, washed and dried (770 mg). Concentration of the filtrate gave a second crop (430 mg). The residues were partioned between water and ethyl acetate (100 ml each) and the aqueous layer was extracted with ethyl acetate (20 ml). The combined organics were washed with water, brine and dried. Removal of solvent gave a brown oil which was purified by flash chromatography on silica (300 g) eluting with cyclohexane/ethyl acetate (3:1) to give a further quantity of product (247 mg). The three crops were combined to give the title compound (1.45 g) as a light brown solid.
  • MH+ 318
  • 1H NMR (CDCl3) δ 2.70 (3H, s), 3.88 (3H, s) 7.08-7.18 (3H, m) 7.84 (2H, m) 8.31 (1H, d, J=10 Hz)
  • Ref: 1 K Novitskii et al, Khim Geterotskil Soedin, 1970 2, 57-62
  • Ref: 2 Barlin G. B., Brown, W. V., J Chem Soc (1968), (12), 1435-45
  • (ii) 2-(4-Fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-6-methylsulfanyl-pyrazolo[1,5-b]pyridazine
  • A mixture of the 2-(4-fluoro-phenyl)-6-(methylthio)-pyrazolo[1,5-b]pyridazine-3-carboxylic acid methyl ester (1.45 g) potassium carbonate (690 mg) in methanol (40 ml) and water (14 ml) was stirred and heated under reflux for 20 hours under nitrogen. The solvents were removed and the resulting solid partioned between ethyl acetate (50 ml) and water (250 ml). The aqueous layer was acidified to pH1 (2 MHCl) and a solid was filtered off (1.0 g, MH+ 304). A mixture of the solid (1.0 g), sodium bicarbonate (557 mg) and NBS (594 mg) were stirred at room temperature for 4 hours. The reaction was poured into water (150 ml) and extracted with ethyl acetate (3×50 ml). The combined extracts were washed with water (50 ml), brine (20 ml), dried and concentrated. The resulting solid (1.015 g, MH+ 338,340), 4-(methanesulphonyl)phenyl boronic acid (902 mg), sodium carbonate (740 mg) and tetrakis(triphenylphosphine)palladium(0) (175 mg) were stirred and heated under nitrogen at reflux in DME (30 mls) and water (15 ml) for 48 hours. The reaction was poured into water and extracted with ethyl acetate (3×50 ml). The combined extracts were dried and the solvent removed to give a brown solid. This was purified on silica (300 g) eluting with cyclohexane, ethyl acetate (1:1) to give the title compound (0.713 g) as a yellow solid.
  • MH+ 414
  • 1H NMR δ (DMSO) 2.65 (3H, s) 3.28 (3H, s) 7.20-7.30 (3H, m) 7.55 (2H, m) 7.62 (4H, d, J=8.5 Hz) 7.95-8.05 (3H, m)
  • (iii) 2-(4-Fluoro-phenyl)-6-methanesulfonyl-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine
  • A suspension of 2-(4-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-6-(methylthio)-pyrazolo[1,5-b]pyridazine (60 mg 0.145) in MeOH (5 ml) and water (2 ml) was stirred with oxone (196 mg 0.32) for 20 hours. The resulting solution was poured into water (50 ml) and extracted with chloroform (3×20 ml). The combined extracts were dried and the solvent removed. Crystallisation of the residue from methanol gave the title compound (60 mg) as a white solid.
  • MH+ 446
  • 1H NMR (DMSO-d6) δ 3.34 (3H, s) 3.53 (3H, s) 7.33 (2H, t, J=9 Hz) 7.62 (2H, m) 7.68 (1H, d, J=8.5 Hz) 8.04 (1H, d, J=10 Hz) 8.52 (1H, d, J=9 Hz)
  • TLC SiO2 Hexane:Ethyl acetate (1:1) Rf 0.24 UV
  • EXAMPLE 5 2-(4-Difluoromethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine
  • Sodium hydride (48 mg, 60% disp. in oil, 1.2 mmol) was added to a solution of 4-[3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazin-2-yl]-phenol (200 mg, 0.55 mmol) in anhydrous dimethylformamide (5 ml). Bromodifluoromethane gas was gently bubbled through the solution for 20 min, then diluted with CH2Cl2 (30 ml). Aqueous workup followed by chromatography on silica gel with CH2Cl2:ethyl acetate (3:1) as eluant then chromatography with CH2Cl2:ethyl acetate (10:1) as eluant gave the title compound (63 mg, 28%) as a white solid.
  • MH+ 416
  • NMR (CDCl3) δ8.38 (1H,dd, J=4 Hz), 8.01 (2H, d, J=8.5 Hz), 7.94 (1H, dd, J=9 & 2 Hz), 7.65 (2H, d, J=8.5 Hz) 7.57 (2H, d, J=8 Hz), 7.10 (3H, m), 6.87-6.27 (1H, t, J=7.4 Hz) 3.15 (3H, s)
  • EXAMPLE 6 4-[2-(4-Ethoxy-phenyl)-pyrazolo[1,5-b]pyridazin-3-yl]-benzenesulfonamide (i) 2-(4-Ethoxy-phenyl)-pyrazolo[1,5-b]pyridazine-3-carboxylic Acid Methyl Ester
  • Diazabicyclo[5.4.0]undec-7-ene (1.47 ml, 2 eq) was added dropwise to a solution of methyl 3-(4-ethoxy-phenyl)-prop-2-ynoic acid (1.0 g) and 1-amino pyridazinium iodide2 (2.19 g) in acetonitrile (10 ml) under nitrogen and stirred for 5 h. Concentration and aqueous workup gave the title compound (1.2 g) as a sticky brown solid.
  • MH+ 298
  • (ii) 2-(4-Ethoxy-phenyl)-pyrazolo[1,5-b]pyridazine-3-carboxylic Acid
  • A mixture of 2-(4-ethoxy-phenyl)-pyrazolo[1,5-b]pyridazine-3-carboxylic acid methyl ester (1.2 g), ethanol (10 ml) and 2N sodium hydroxide (10 ml) was heated to 800 for 1.5 h. The mixture was allowed to cool and acidified to pH 1 with 2N hydrochloric acid. The title compound was isolated by filtration as a brown solid (716 mg, 63%).
  • MH+ 284
  • (iii) 2-(4-Ethoxy-phenyl)-3-iodo-pyrazolo[1,5-b]pyridazine
  • A mixture of 2-(4-ethoxy-phenyl)-pyrazolo[1,5-b]pyridazine-3-carboxylic acid (710 mg), N-iodosuccinimide (678 mg) and sodium bicarbonate (717 mg) in DMF (8 ml) was stirred for 4 h. A further quantity of N-iodosuccinimide(100 mg) was added and stirring continued for 2 h. Aqueous workup gave a dark brown solid which was purified by SPE with dichloromethane as eluant. This gave the title compound as an orange-brown solid (429 mg, 47%).
  • MH+ 366
  • (iv) 4-[2-(4-Ethoxy-phenyl)-pyrazolo[1,5-b]pyridazin-3-yl]-benzenesulfonamide
  • A mixture of 4-iodobenzenesulphonamide (0.311 g), dipinacoldiborane1 (0.279 g), potassium acetate (486 mg) and [1,1′-bis(diphenylphosphino)-ferrocene]palladium(II) chloride complex with dichloromethane (1:1) (0.45 g) in dimethylformamide (8 ml) was heated under nitrogen at 800 for 2 h. The cooled reaction mixture was concentrated in vacuo and the residue suspended in 1,2 dimethoxyethane (10 ml), 2-(4-ethoxy-phenyl)-3-iodo-pyrazolo[1,5-b]pyridazine (0.4 g) was added together with 2N sodium carbonate (4 ml) and tetrakis(triphenylphosphine)palladium (0) (20 mg) and the mixture heated at reflux under nitrogen for 18 hours. The cooled reaction mixture was poured into water (60 ml) and the suspension extracted with ethyl acetate (3×60 ml). The organic extracts were combined, dried (Na2SO4) and concentrated. The residue was purified by chromatography eluting with dichloromethane/ethyl acetate (3:1) to give the title compound as a yellow solid (0.116 g, 27%).
  • MH+ 395
  • NMR (CDCL3) δ 8.32 (1H, dd, J=4 & 2 Hz), 7.97 (2H, d, J=8 Hz), 7.89 (1H, dd, J=9 & 2 Hz), 7.54 (4H, m), 7.04 (1H, dd, J=9 & 4 Hz), 6.88 (2H, d, J=9 Hz), 1.43 (3H, t, J=7 Hz)
  • Ref: 1 R. Miyaura et al J.Org.Chem., 1995,60,7508-7510.
  • EXAMPLE 7 6-Difluoromethoxy-2-(3-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine (i) 1-(2,2-Dibromo-vinyl)-3-fluoro-benzene
  • To a stirred cooled (ice/salt, 0°) solution of carbon tetrabromide (48.82 g) in anhydrous CH2Cl2 (200 ml) was added portionwise over 3 minutes, triphenylphosphine (77.1 g), maintaining the temperature below 100. The resulting orange suspension was stirred at 0° for 1 hour before adding to it, 3-fluorobenzaldehyde (7.8 ml). After the addition was complete, the suspension was stirred at 0° for 1 hour then quenched by the addition of water (75 ml). The organic phase was separated and washed with brine (75 ml), dried (Na2SO4) and evaporated to dryness. The residual gum was poured into cyclohexane (1 L) and stirred for 30 minutes. The organic phase was decanted and the residue taken up into CH2Cl2 and poured into cyclohexane (1 L). This procedure was repeated twice more and the combined organic phases concentrated to ˜100 ml and passed through silica gel. The filtrate was concentrated to give the title compound as a mobile yellow oil (24 g, 100%).
  • MH+ 280, MH279
  • NMR (CDCl3) δ 7.05 (1H, tm, J=9 Hz) 7.3 (3H, m) 7.45 (1H, s)
  • (ii) (3-Fluoro-phenyl)-propynoic Acid Methyl Ester
  • To a stirred solution of 1-(2,2-dibromo-vinyl)-3-fluoro-benzene (23.8 g) in anhydrous THF (350 ml) cooled to −780 was added dropwise over 30 minutes, n-butyllithium (2.2 eq, 1.6M in hexanes). The mixture was stirred for a further 30 minutes at −780 before methyl chloroformate (11.6 g, 9.5 ml) was added and the resultant mixture allowed to warm to 0° for 1 hour before being diluted with 1:1 saturated aqueous sodium bicarbonate:ammonium chloride (100 ml) and extracted into ether (2×100 ml). The combined organic extract was washed with brine (25 ml), dried (Na2SO4) and evaporated to dryness to give the title compound as a brown oil (16.7 g, 100%).
  • MH173
  • NMR (CDCl3) δ 7.4-7.1 (4H, m) 3.85 (3H, s, CO2Me)
  • (iii) 2-(3-Fluoro-phenyl)-6-methoxy-pyrazolo[1,5-b]pyridazine-3-carboxylic Acid Methyl Ester
  • 1,8-Diazabicyclo[5.4.0]undec-7-ene (5 ml) was added to a stirred, chilled, mixture of (3-fluoro-phenyl)-propynoic acid methyl ester (2.67 g) and 1-amino-3-methoxy-pyridazin-1-ium mesitylene sulphonate (4.89 g) in acetonitrile (80 ml) and the mixture was stirred at 0° for 1 hour then at ambient temperature for 18 hours. The mixture was concentrated in vacuo, and partitioned between ethyl acetate (150 ml) and water (150 ml). The aqueous phase was separated and further extracted with ethyl acetate (2×100 ml). The combined organic extracts were washed with water (2×50 ml), brine (25 ml), dried (MgSO4), filtered and evaporated in vacuo to give a solid which was triturated with anhydrous ether: petroleum ether (1:0.5) to give the title compound as a brown solid (2.4 g, 53%).
  • MH+ 302
  • 1H NMR (CDCl3) δ 12.8 (1H, br s); 8.4 (1H, d, J=10 Hz) 7.7-7.6 (2H, m) 7.42 (1H, q, J=8 Hz) 7.15 (1H, td, J 8 & 3 Hz) 6.95 (1H, d, J=10 Hz) 4.1 (3H, s) 3.88 (3H, s)
  • (iv) 2-(3-Fluoro-phenyl)-6-methoxy-pyrazolo[1,5-b]pyridazine-3-carboxylic Acid
  • 2N sodium hydroxide (50 ml) was added to a solution of 2-(3-fluoro-phenyl)-6-methoxy-pyrazolo[1,5-b]pyridazine-3-carboxylic acid methyl ester (2.3 g) in absolute ethanol (50 ml) and the resulting mixture heated to reflux for three hours. The cooled reaction mixture was poured slowly into a stirred solution of 2N hydrochloric acid (300 ml). The resulting suspension was stirred at ambient temperature for 1 hour then filtered and the filter cake washed with water and dried in vacuo at 60° to give the title compound as an off-white solid (2.0 g, 91%).
  • MH+ 288
  • 1H NMR (DMSO) δ 8.45 (1H, d, J=10 Hz); 7.67 (2H, m); 7.5 (1H, q, J=7 Hz); 7.3 (1H, td, J 7& 2 Hz); 7.21 (1H, d, J=10 Hz); 4.0 (3H, s)
  • (v) 3-Bromo-2-(3-fluoro-phenyl)-6-methoxy-pyrazolo[1,5-b]pyridazine
  • To a stirred solution of 2-(3-fluoro-phenyl)-6-methoxy-pyrazolo[1,5-b]pyridazine-3-carboxylic acid (2.0 g) in anhydrous DMF (20 ml) was added n-bromosuccinimide (1.78 g) and the resulting solution stirred at ambient temperature for 3 hours. The reaction mixture was diluted with ethyl acetate (800 ml) and washed sequentially with water (10×100 ml) and sat. brine (25 ml), dried (Na2SO4), and concentrated to give the title compound as a buff solid (2.1 g, 93%).
  • MH+ 323, MH321
  • 1H NMR (CDCl3) 7.9 (2H, m) 7.8 (1H, d, J=10 Hz); 7.45 (1H, m); 7.1 91H, td, J 8 & 2 Hz); 6.78 (1H, d, J=10 Hz); 4.1 (3H, s)
  • (vi) 6-Difluoromethoxy-2-(3-fluoro-phenyl)-pyrazolo[1,5-b]pyridazine
  • Portions of 3-bromo-2-(3-fluoro-phenyl)-6-methoxy-pyrazolo[1,5-b]pyridazine (400 mg, 2.1 g total) were placed in individual Reactivials equipped with a magnetic stirrer bar. Pyridine hydrochloride (10 eq) was added to each vial, the vials sealed, and heated to 2000 for 3 hours. The vials were allowed to cool to ˜140° before opening and the contents poured into ice/water. The resulting mixture was extracted into ethyl acetate (3×100 ml) and the combined organic extracts washed with water (7×75 ml), dried (Na2SO4) and evaporated to give the des-bromo phenol as a brown solid (1.0 g, MH+ 230). This solid was dissolved in anhydrous DMF (10 ml) and sodium hydride (60% dispersion in mineral oil, 200 mg) added portionwise. After stirring for 20 minutes at ambient temperature the solution was transferred to a small cooled autoclave and bromodifluoromethane (5 ml, xs, condensed at −30°) added. The autoclave was then sealed, allowed to warm to ambient temperature and stirred for 36 hours. The resulting solution was diluted with ethyl acetate (200 ml), washed with water (10×20 ml), dried (Na2SO4), concentrated and the residual gum purified by flash column chromatography with cyclohexane:ethyl acetate (4:1) as eluant. This gave the title compound as a solid (652 mg, 60%).
  • MH+ 280 MH278
  • NMR (DMSO) δ 8.42(1H, d, J=10 Hz) 7.85 (1H, d, J=8 Hz) 7.78 (1H, t, J=70 Hz) 7.55 (1H, q, J=8 Hz) 7.38 (1H, s) 7.25 (1H, m) 7.17 (1H, d, J=10 Hz)
  • (vii) 3-Bromo-6-difluoromethoxy-2-(3-fluoro-phenyl)-pyrazolo[1,5-b]pyridazine
  • N-bromo succinimide (195 mg) was added to a solution of 6-difluoromethoxy-2-(3-fluoro-phenyl)-pyrazolo[1,5-b]pyridazine (251 mg) and sodium bicarbonate (185 mg) in anhydrous DMF (10 ml) and stirred for 18 h. The reaction mixture was diluted with ethyl acetate (300 ml) and washed with water (10×20 ml), brine (20 ml), dried (Na2SO4) and concentrated to give the title compound as a solid (293 mg, 91%).
  • MH+ 359, MH356/357
  • NMR (DMSO) δ 8.36 (1H, d, J=10 Hz) 7.88 (1H, d, J=8 Hz) 7.78 (1H, t, J=70 Hz, OCHF2) 7.77 (1H, dm, J=10 Hz) 7.62 (1H, dt, J 8 & 6 Hz) 7.38 (1H, dt, J 9 & 2 Hz) 7.3 (1H, d, J=10 Hz)
  • (viii) 6-Difluoromethoxy-2-(3-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine
  • To a stirred solution of 3-bromo-6-difluoromethoxy-2-(3-fluoro-phenyl)-pyrazolo[1,5-b]pyridazine (286 mg) in DMF(20 ml) was added 2N aq sodium carbonate (10 ml). To this mixture was added 4-methanesulfonyl-phenylboronic acid (180 mg) and tetrakis triphenylphosphine palladium (0) (34 mg). The resulting mixture was stirred and heated to reflux for 18 hours. The cooled reaction mixture was diluted with ethyl acetate (300 ml) and the organic solution washed with water (10×30 ml) and brine (30 ml), dried (Na2SO4) and evaporated to give a gum which was purified by flash column chromatography with chloroform:ethyl acetate (50:1 to 5:1) as eluant. Combination of appropriate fractions and concentration gave the title compound as an off-white solid (132 mg, 37%).
  • MH+ 434
  • 1H NMR(CDCl3) δ 8.02 (1H, d, J=9 Hz); 7.95 (2H, d, J=10 Hz); 7.58 (1H, d, 9 Hz); 7.52 (1H, t, J=70 Hz); 7.32 (3H, m); 7.08 (1H, m); 6.9 (1H, d, J=9 Hz); 3.15 (3H, s).
  • Biological Data
  • Inhibitory activity against human COX-1 and COX-2 was assessed in COS cells which had been stably transfected with cDNA for human COX-1 and human COX-2. 24 Hours prior to experiment, COS cells were transferred from the 175 cm2 flasks in which they were grown, onto 24-well cell culture plates using the following procedure. The incubation medium (Dulbecco's modified eagles medium (DMEM) supplemented with heat-inactivated foetal calf serum (10% v/v), penicillin (100 IU/ml), streptomycin (100 μg/ml) and geneticin (600 μg/ml)) was removed from a flask of confluent cells (1 flask at confluency contains approximately 1×107 cells). 10 ml of phosphate buffered saline (PBS) was added to the flask to wash the cells. Having discarded the PBS, cells were then rinsed in 10 ml trypsin for 20 seconds, after which the trypsin was removed and the flask placed in an incubator (37°) for 1-2 minutes until cells became detached from the flask. The flask was then removed from the incubator and cells resuspended in 10 ml of fresh incubation medium. The contents of the flask was transferred to a 250 ml sterile container and the volume of incubation medium subsequently made up to 100 ml. 1 ml cell suspension was pipetted into each well of 4×24-well cell culture plates. The plates were then placed in an incubator (37° C., 95% air/5% CO2) overnight. If more than 1 flask of cells were required, the cells from the individual flasks were combined before being dispensed into the 24-well plates.
  • Following the overnight incubation, the incubation medium was completely removed from the 24-well cell culture plates and replaced with 250 μl fresh DMEM (37° C.). The test compounds were made up to 250× the required test concentration in DMSO and were added to the wells in a volume of 1 μl. Plates were then mixed gently by swirling and then placed in an incubator for 1 hour (37° C., 95% air/5% CO2). Following the incubation period, 10 μl of arachidonic acid (750 μM) was added to each well to give a final arachidonic acid concentration of 30 μM. Plates were then incubated for a further 15 minutes, after which the incubation medium was removed from each well of the plates and stored at −20° C., prior to determination of prostaglandin E2 (PGE2) levels using enzyme immunoassay. The inhibitory potency of the test compound was expressed as an IC50 value, which is defined as the concentration of the compound required to inhibit the PGE2 release from the cells by 50%. The selectivity ratio of inhibition of COX-1 versus COX-2 was calculated by comparing respective IC50 values.
  • The following IC50 values for inhibition of COX-2 and COX-1 were obtained for compounds of the invention:
    Example No. COX-2: IC50(nM) COX-1: IC50(nM)
    1(v) 35 >100,000
    2(ii) <10 3,880
    3(ii) 3 >100,000
    4(iii) 370 >100,000
    5 21 >100,000
    6(iv) 0.44 3828
    7(viii) 16 >55,200

Claims (23)

1-13. (canceled)
14. A pharmaceutical composition comprising a compound of formula (I)
Figure US20050113377A1-20050526-C00011
or a pharmaceutically acceptable salt, solvate, ester or salt or solvate of such ester, of a compound of formula (I) in which:
R0 is halogen, C1-6alkyl, C1-6alkoxy, C1-6alkoxy substituted by one or more fluorine atoms, or O(CH2)nNR4R5;
R1 and R2 are independently selected from H, C1-6alkyl, C1-6alkyl substituted by one or more fluorine atoms, C1-6alkoxy, C1-6hydroxyalkyl, SC1-6alkyl, C(O)H, C(O)C1-6alkyl, C1-6alkylsulphonyl, C1-6alkoxy substituted by one or more fluorine atoms, O(CH2)nCO2C1-6alkyl, O(CH2)nSC1-6alkyl, (CH2)nNR4R5, (CH2)nSC1-6alkyl or C(O)NR4R5; with the proviso that when R0 is at the 4-position and is halogen, at least one of R1 and R2 is C1-6alkylsulphonyl, C1-6alkoxy substituted by one or more fluorine atoms, O(CH2)nCO2C1-6alkyl, O(CH2)nSC1-6alkyl, (CH2)nNR4R5 or (CH2)nSC1-6 alkyl, C(O)NR4R5;
R3 is C1-6alkyl or NH2;
R4 and R5 are independently selected from H and C1-6alkyl; and n is 1-4;
and an inhibitor of the release, or action, of tumour necrosis factor α.
15. The pharmaceutical composition according to claim 14 further comprising one or more physiologically acceptable carriers or excipients.
16. A method of treating an animal subject suffering from a condition which is mediated by selective inhibition of COX-2, said method comprising administering to said subject an effective amount of the pharmaceutical composition according to claim 14.
17. The method according to claim 16, wherein said animal subject is a human.
18. The method according to claim 16, wherein said condition which is mediated by selective inhibition of COX-2 is selected from the group consisting of pain, fever and inflammation.
19. The method according to claim 16, wherein said condition which is mediated by selective inhibition of COX-2 is selected from the group consisting of rheumatic fever, influenza, cold, lower back pain, neck pain, headache, toothache, sprains, strains, myositis, neuralgia, synovitis, arthritis, rheumatoid arthritis, degenerative joint diseases, osteoarthristis, gout, ankylosing spondylitis, tendinitis, bursitis, psoriasis, eczema, burns, dermatitis, sports injuries, and injuries arising from surgical and dental procedures.
20. The method according to claim 16, wherein said condition which is mediated by selective inhibition of COX-2 is selected from the group consisting of colonic cancer, stroke, epilepsy, epileptic seizures, dysmenorrhoea, premature labour, asthma, allergic rhinitis, respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, inflammation in vascular disease, inflammation in migraine, inflammation in periarteritis, inflammation in nodosa, inflammation in thyroiditis, inflammation in aplastic anemia, inflammation in Hodgkin's disease, inflammation in sclerodoma, inflammation in type 1 diabetes, inflammation in myasthenia gravis, inflammation in multiple sclerosis, inflammation in sorcoidosis, inflammation in nephrotic syndrome, inflammation in Bechet's syndrome, inflammation in polymyositis, inflammation in gingivitis, inflammation in conjunctivitis, inflammation in myocardial ischemia, retinitis, retinopathies, uveitis and acute injury to the eye.
21. The method according to claim 16, wherein said condition which is mediated by selective inhibition of COX-2 is selected from the group consisting of dementia, degenerative dementia, senile dementia, Alzheimer's disease, Pick's disease, Huntington's chorea, Parkinson's disease, Creutzfeldt-Jakob disease, vascular dementia, dementia associated with intracranial space occupying lesions, dementia associated with trauma, dementia associated with infections, dementia associated with HIV infections, dementia associated with metabolism, dementia associated with toxins, dementia associated with anoxia, dementia associated with vitamin deficiency, mild cognitive impairment associated with aging and Age Associated Memory Impairment.
22. The method according to claim 16 wherein said condition which is mediated by selective inhibition of COX-2 is an inflammatory disorder.
23. The method according to claim 16 wherein said condition which is mediated by selective inhibition of COX-2 is arthritis.
24. The method according to claim 16 wherein said condition which is mediated by selective inhibition of COX-2 is rheumatoid arthritis or osteoarthritis.
25. The method according to claim 16 wherein said condition which is mediated by selective inhibition of COX-2 is inflammation in migraine.
26. The method according to claim 16 wherein said condition which is mediated by selective inhibition of COX-2 is inflammation in multiple sclerosis.
27. A pharmaceutical composition comprising a compound selected from the group consisting of:
3-(4-methanesulfonyl-phenyl)-2-(4-methoxy-phenyl)-pyrazolo[1,5-b]pyridazine;
6-difluoromethoxy-2-(4-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
2-(4-fluoro-phenyl)-6-methanesulfonyl-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
2-(4-difluoromethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
4-[2-(4-ethoxy-phenyl)-pyrazolo[1,5-b]pyridazin-3-yl]-benzenesulfonamide; and
6-difluoromethoxy-2-(3-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
and pharmaceutically acceptable salts, solvates, esters and salts or solvates of such esters, thereof
and an inhibitor of the release, or action, of tumour necrosis factor α.
28. The pharmaceutical composition according to claim 27 further comprising one or more physiologically acceptable carriers or excipients.
29. The pharmaceutical composition according to claim 27, wherein the compound is selected from the group consisting of
2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
6-difluoromethoxy-2-(3-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
and pharmaceutically acceptable salts, solvates, esters and salts or solvates of such ester, thereof.
30. A method of treating an animal subject suffering from a condition which is mediated by selective inhibition of COX-2, said method comprising administering to said subject an effective amount of the pharmaceutical composition according to claim 29.
31. The method according to claim 30 wherein said condition which is mediated by selective inhibition of COX-2 is an inflammatory disorder.
32. The method according to claim 30 wherein said condition which is mediated by selective inhibition of COX-2 is arthritis.
33. The method according to claim 30 wherein said condition which is mediated by selective inhibition of COX-2 is rheumatoid arthritis or osteoarthritis.
34. The method according to claim 30 wherein said condition which is mediated by selective inhibition of COX-2 is inflammation in migraine.
35. The method according to claim 30 wherein said condition which is mediated by selective inhibition of COX-2 is inflammation in multiple sclerosis.
US10/974,893 1997-09-05 2004-10-27 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors Abandoned US20050113377A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/974,893 US20050113377A1 (en) 1997-09-05 2004-10-27 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9718792.6A GB9718792D0 (en) 1997-09-05 1997-09-05 Chemical compounds
GB9718792.6 1997-09-05
GBGB9727116.7A GB9727116D0 (en) 1997-12-23 1997-12-23 Chemical compounds
GB9727116.7 1997-12-23
US10/212,513 US6861429B2 (en) 1997-09-05 2002-08-05 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
US10/974,893 US20050113377A1 (en) 1997-09-05 2004-10-27 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/212,513 Continuation US6861429B2 (en) 1997-09-05 2002-08-05 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors

Publications (1)

Publication Number Publication Date
US20050113377A1 true US20050113377A1 (en) 2005-05-26

Family

ID=26312181

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/508,029 Expired - Fee Related US6451794B1 (en) 1997-09-05 1998-09-03 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors
US10/212,513 Expired - Fee Related US6861429B2 (en) 1997-09-05 2002-08-05 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
US10/212,514 Expired - Fee Related US6831097B2 (en) 1997-09-05 2002-08-05 2,3-diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
US10/974,893 Abandoned US20050113377A1 (en) 1997-09-05 2004-10-27 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US09/508,029 Expired - Fee Related US6451794B1 (en) 1997-09-05 1998-09-03 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors
US10/212,513 Expired - Fee Related US6861429B2 (en) 1997-09-05 2002-08-05 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
US10/212,514 Expired - Fee Related US6831097B2 (en) 1997-09-05 2002-08-05 2,3-diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors

Country Status (28)

Country Link
US (4) US6451794B1 (en)
EP (3) EP1510519B1 (en)
KR (1) KR100382619B1 (en)
CN (1) CN1155600C (en)
AP (1) AP1354A (en)
AT (3) ATE281458T1 (en)
AU (1) AU744997B2 (en)
BG (1) BG64420B1 (en)
BR (1) BR9812046A (en)
CA (1) CA2303152A1 (en)
DE (3) DE69827419T2 (en)
DK (1) DK1032575T3 (en)
EA (1) EA002775B1 (en)
EE (1) EE04617B1 (en)
ES (3) ES2231757T3 (en)
HR (1) HRP20000122B1 (en)
HU (1) HUP0003644A3 (en)
IL (1) IL134688A (en)
IS (1) IS5389A (en)
NO (1) NO315559B1 (en)
NZ (1) NZ502985A (en)
PL (1) PL194557B1 (en)
PT (1) PT1032575E (en)
SK (1) SK283922B6 (en)
TR (1) TR200000595T2 (en)
TW (1) TW570922B (en)
WO (1) WO1999012930A1 (en)
YU (1) YU11900A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1510519B1 (en) * 1997-09-05 2006-02-15 Glaxo Group Limited Pharmaceutical compositions comprising 2,3-diarylpyrazolo[1,5-B]pyridazine derivatives
DE69919887T2 (en) 1998-11-03 2005-09-15 Glaxo Group Ltd., Greenford PYRAZOLOPYRIDINE DERIVATIVE AS SELECTIVE COX-2 INHIBITORS
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP2002538157A (en) 1999-02-27 2002-11-12 グラクソ グループ リミテッド Pyrazolopyridine
GB9929039D0 (en) * 1999-12-08 2000-02-02 Glaxo Group Ltd Medicaments
GB9930358D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
US6649629B2 (en) 1999-12-23 2003-11-18 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
GB0002312D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
NZ524252A (en) 2000-07-20 2004-03-26 Lauras As Cox-2 inhibitors for treating HIV and AIDS
PE20020506A1 (en) * 2000-08-22 2002-07-09 Glaxo Group Ltd PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS
GB0021494D0 (en) * 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
GB0025449D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
ES2243579T3 (en) 2000-12-15 2005-12-01 Glaxo Group Ltd DERIVATIVES OF PIRAZOLOPIRIDENO.
DE60112609T2 (en) 2000-12-15 2006-01-19 Glaxo Group Ltd., Greenford pyrazolopyridines
ATE274515T1 (en) 2001-03-08 2004-09-15 Smithkline Beecham Corp PYRAZOLOPYRIDINE DERIVATIVES
US7034030B2 (en) 2001-03-30 2006-04-25 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapeutic compounds
WO2002083672A1 (en) 2001-04-10 2002-10-24 Smithkline Beecham Corporation Antiviral pyrazolopyridine compounds
DE60204452T2 (en) 2001-04-27 2005-12-15 Smithkline Beecham Corp. [1,5] pyridine derivatives
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
GB0112810D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112802D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
EP1401836B1 (en) 2001-06-21 2006-08-23 SmithKline Beecham Corporation Imidazo¬1,2-a|pyridine derivatives for the prophylaxis and treatment of herpes viral infections
DE60211539T2 (en) 2001-10-05 2006-09-21 Smithkline Beecham Corp. IMIDAZOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HERPES VIRUS INFECTION
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
DE60222465T2 (en) 2001-12-11 2008-06-05 Smithkline Beecham Corp. PYRAZOLOPYRIDINE DERIVATIVES AS ANTI-HERPING AGENTS
AU2002357164A1 (en) 2001-12-17 2003-06-30 Smithkline Beecham Corporation Pyrazolopyridazine derivatives
KR100686537B1 (en) * 2001-12-28 2007-02-27 씨제이 주식회사 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor
KR100840907B1 (en) * 2001-12-28 2008-06-24 씨제이제일제당 (주) Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor
US7125898B2 (en) * 2002-02-12 2006-10-24 Smithkline Beecham Corporation Nicotinamide derivatives useful as p38 inhibitors.
GB0206200D0 (en) * 2002-03-15 2002-05-01 Glaxo Group Ltd Pharmaceutical compositions
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
EP1546128B1 (en) 2002-08-19 2006-05-03 Glaxo Group Limited Pyrimidine derivatives as selective cox-2 inhibitors
UY27939A1 (en) 2002-08-21 2004-03-31 Glaxo Group Ltd COMPOUNDS
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
WO2004033454A1 (en) 2002-10-03 2004-04-22 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
GB0227443D0 (en) * 2002-11-25 2002-12-31 Glaxo Group Ltd Pyrimidine derivatives
ES2213485B1 (en) * 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. DERIVATIVES OF 2-FENILPIRAN-4-ONA.
ES2214130B1 (en) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 2-3'-BIPIRIDINES.
ES2214129B1 (en) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-FENILFURAN-2-ONAS.
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
PL1745791T3 (en) 2003-05-07 2013-11-29 Osteologix As Treating cartilage/bone conditions with water-soluble strontium salts
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0319037D0 (en) * 2003-08-13 2003-09-17 Glaxo Group Ltd 7-Azaindole Derivatives
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
AR052429A1 (en) 2004-12-23 2007-03-21 Glaxo Group Ltd ARILPIRIDINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PROCEDURE TO PREPARE IT
CA2590997A1 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer`s disease
US7767710B2 (en) * 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
GB201007791D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel compounds
US9115132B2 (en) 2010-07-09 2015-08-25 Convergence Pharmaceuticals Limited Tetrazole compounds as calcium channel blockers
ES2541416T3 (en) 2011-01-19 2015-07-20 Convergence Pharmaceuticals Limited Piperazine derivatives as calcium channel blockers Cav2.2
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease
CN115611901B (en) * 2021-07-16 2024-04-30 华南理工大学 Azepine compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985444A (en) * 1989-01-23 1991-01-15 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and processes for preparation thereof
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
US5296490A (en) * 1987-06-15 1994-03-22 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutically useful pyrazolopyridines
US5300478A (en) * 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
US5498774A (en) * 1989-06-23 1996-03-12 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6136839A (en) * 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6861429B2 (en) * 1997-09-05 2005-03-01 Smithkline Beecham Corporation 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002941A (en) 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
KR920702621A (en) 1989-06-13 1992-10-06 스튜어트 알. 슈터 Inhibition of Interleukin-1 or Tumor Factor Factor Production by Monocytes and / or Macrophages
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
WO1991019497A1 (en) 1990-06-12 1991-12-26 Smithkline Beecham Corporation Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
GB9015764D0 (en) 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
FR2699077B1 (en) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application of anticonvulsants in the treatment of neurological lesions linked to trauma.
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CA2180651A1 (en) 1994-01-10 1995-07-13 Yves Ducharme Phenyl heterocycles as cox-2 inhibitors
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
HUP9801602A3 (en) * 1995-04-04 1999-01-28 Glaxo Group Ltd Imidazo[1,2-a]pyridine derivatives, process for their production, pharmaceutical compositions and use thereof
US6342510B1 (en) * 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
GB9513508D0 (en) * 1995-07-03 1995-09-06 Fujisawa Pharmaceutical Co Quinazoline derivatives
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296490A (en) * 1987-06-15 1994-03-22 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutically useful pyrazolopyridines
US4985444A (en) * 1989-01-23 1991-01-15 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and processes for preparation thereof
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
US5498774A (en) * 1989-06-23 1996-03-12 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
US5300478A (en) * 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US5990148A (en) * 1995-06-12 1999-11-23 G.D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6136839A (en) * 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6861429B2 (en) * 1997-09-05 2005-03-01 Smithkline Beecham Corporation 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds

Also Published As

Publication number Publication date
NO20001102L (en) 2000-05-03
YU11900A (en) 2002-11-15
DE69827419T2 (en) 2005-10-27
TW570922B (en) 2004-01-11
AU744997B2 (en) 2002-03-07
EP1032575A1 (en) 2000-09-06
BG104279A (en) 2000-12-29
SK283922B6 (en) 2004-05-04
ES2203985T3 (en) 2004-04-16
US6451794B1 (en) 2002-09-17
PT1032575E (en) 2003-11-28
EP1369421B1 (en) 2004-11-03
CN1278263A (en) 2000-12-27
HUP0003644A2 (en) 2001-09-28
CN1155600C (en) 2004-06-30
WO1999012930A1 (en) 1999-03-18
SK2942000A3 (en) 2001-03-12
KR100382619B1 (en) 2003-05-09
EE200000113A (en) 2000-12-15
NO20001102D0 (en) 2000-03-03
DE69816651T2 (en) 2004-04-01
DK1032575T3 (en) 2003-10-20
US20030040517A1 (en) 2003-02-27
EE04617B1 (en) 2006-04-17
BR9812046A (en) 2000-09-26
IS5389A (en) 2000-02-25
IL134688A0 (en) 2001-04-30
JP3167700B2 (en) 2001-05-21
NZ502985A (en) 2002-04-26
US20030008872A1 (en) 2003-01-09
ATE281458T1 (en) 2004-11-15
AU9439598A (en) 1999-03-29
EP1510519B1 (en) 2006-02-15
BG64420B1 (en) 2005-01-31
ES2256817T3 (en) 2006-07-16
EP1369421A1 (en) 2003-12-10
ATE317845T1 (en) 2006-03-15
JP2001515901A (en) 2001-09-25
US6861429B2 (en) 2005-03-01
PL339059A1 (en) 2000-12-04
TR200000595T2 (en) 2000-12-21
HRP20000122A2 (en) 2001-02-28
DE69816651D1 (en) 2003-08-28
US6831097B2 (en) 2004-12-14
CA2303152A1 (en) 1999-03-18
KR20010023669A (en) 2001-03-26
DE69833464D1 (en) 2006-04-20
HUP0003644A3 (en) 2002-11-28
EA200000188A1 (en) 2000-10-30
HRP20000122B1 (en) 2003-06-30
DE69833464T2 (en) 2006-08-24
EP1032575B1 (en) 2003-07-23
EP1510519A1 (en) 2005-03-02
NO315559B1 (en) 2003-09-22
IL134688A (en) 2005-05-17
ES2231757T3 (en) 2005-05-16
AP2000001753A0 (en) 2000-03-31
ATE245649T1 (en) 2003-08-15
PL194557B1 (en) 2007-06-29
AP1354A (en) 2004-12-29
DE69827419D1 (en) 2004-12-09
EA002775B1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
US6831097B2 (en) 2,3-diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
EP1157025B1 (en) Pyrazolopyridines
US7223772B1 (en) Pyrazolopyridine derivatives as selective cox-2 inhibitors
TWI265031B (en) Novel pharmaceuticals
NZ304886A (en) Imidazo [1,2a] pyridine derivatives, preparation and pharmaceutical compositions thereof
EP1493735B1 (en) Pyrimidine derivatives useful as selective cox-2 inhibitors
JP3167700B1 (en) 2,3-Diaryl-pyrazolo [1,5-B] pyridazine derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
MXPA00002203A (en) 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors
CZ2000800A3 (en) 2,3-diarylpyrazolo /1,5 - b/ pyridazine derivatives
ZA200103344B (en) Pyrazolopyridine derivatives as selective COX-2 inhibitors.
MXPA97007379A (en) Derivatives of imidazo [1,2-a] pirid

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION